OrientBio - provides experimental animials and developes hair growth solution

OrientBio - provides experimental animials and developes hair growth solution
(Stock code: 002630)
http://www.orient.co.kr
http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20160215000464

This company provides many experimental animals to pharmaceutical companies and life science institutes. Also, this company is in Phase 1 clinical trial to develop a hair growth solution, which is named OND-1.


1. Providing experimental animals

OrientBio produces and provides rodents for making vaccine and mid or large-sized experimental animals like beagles. Rodents are derived from one of big experimental animal producer, Charles River Laboratories, in USA, and beagles have been produced and provided based on a partnership with a company Covance.

OrientBio also has a plan to provide experimental primates, cuz the demand primates has been increasing in South Korea, and there is no domestic primates provider. In addition, experimental primates would be essential for the process of bio-similar developments so that the plan to produce and provide high quality of experimental primate is a good try.


2. Development of hair growth solution

There are only two FDA-approved hair growth medicines in the market. Rogaine (5% Minoxidil, percutaneous medication) and Propecia (1 mg Finasteride, oral medication) are those medicine.

The size of hair related market is literally huge as you know. It is estimated that the world size of hair market is around 83.1 billion dollars in 2016.
http://www.statista.com/statistics/254608/global-hair-care-market-size

The effectiveness of a hair growth solution from OrientBio, OND-1, is better than Rogaine. I would say that when Phase I clinical trial can be finished with the final and successful product launch, Profecia may be replaced with OND-1 in the market.

Here are a time table for clinical trial below.
   <Domestic Phase 1 clinical trial>
2014 Dec: Try with 20% Velesco solution and test method
2015 Mar: Submit new clinical test report
2015 May: Expected clinical license in South Korea
2015 Nov: Clinical Phase 1 (Clinical IRB in Bundang Hospital, Seoul, South Korea)
2016 the first half: Complete Phase 1 clinical trial in Korea
   <Domestic Phase 2a clinical trial>
2016 Jun - 2016 Dec: Accepted 2 clinical trials in Korea
   <USA Phase 2b clinical trial>
2017 Feb - : Conversion and optimization with MN (animal experiment, 4 weeks application observation)
- 2018 Feb: Target goal of medication efficiency (compare with minoxidil), clinical trial for patients with hair losing patients.

I hope that the development of hair growth solution OND-1 from OrientBio would be successful so that thin hair people could have dense hair cuz the effectiveness of Rogaine is not that good, and they could ease the financial burden to buy Profecia (2 dollars per a tablet) soon. Lol